124 related articles for article (PubMed ID: 34889109)
1. Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019.
Duvalyan A; Pandey A; Vaduganathan M; Essien UR; Halm EA; Fonarow GC; Sumarsono A
J Am Heart Assoc; 2021 Dec; 10(24):e022644. PubMed ID: 34889109
[No Abstract] [Full Text] [Related]
2. Recommendations for Lowering Prescription Drug Spending in Public Programs.
Jazowski SA; Dusetzina SB
Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
[No Abstract] [Full Text] [Related]
3. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
4. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
5. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
6. Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2018 Jul; 37(7):1048-1056. PubMed ID: 29985706
[TBL] [Abstract][Full Text] [Related]
7. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
8. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
9. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
Watanabe JH; Chau DL; Hirsch JD
J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
[TBL] [Abstract][Full Text] [Related]
10. Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
Sumarsono A; Vaduganathan M; Ajufo E; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2020 Mar; 5(3):336-339. PubMed ID: 31738371
[TBL] [Abstract][Full Text] [Related]
11. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
12. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
13. Medicare part D after 2 years.
Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
15. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
[TBL] [Abstract][Full Text] [Related]
17. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
18. Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability.
Buckley LF; Ting C; Fatani N; Fanikos J
J Clin Lipidol; 2020; 14(3):315-321.e4. PubMed ID: 32362514
[TBL] [Abstract][Full Text] [Related]
19. Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
Daniel H; Bornstein SS;
Ann Intern Med; 2019 Dec; 171(11):825-827. PubMed ID: 31711137
[TBL] [Abstract][Full Text] [Related]
20. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]